Literature DB >> 32340988

Effect of the Lysin Exebacase on Cardiac Vegetation Progression in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Endocarditis as Determined by Echocardiography.

Dario Lehoux1, Arnold S Bayer2,3, Sonia U Shah4,2,3, Yan Q Xiong2,3, Wessam Abdelhady2, James Iwaz4, Youngju Pak2,3, Raymond Schuch5, Cara Cassino5.   

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) poses significant therapeutic challenges related to its frequency in clinical infections, innate virulence properties, and propensity for multiantibiotic resistance. MRSA is among the most common causes of endovascular infections, including infective endocarditis (IE). Our objective was to employ transthoracic echocardiography (TTE) to evaluate the effect of exebacase, a novel direct lytic agent, in experimental aortic valve MRSA IE. TTE was utilized to evaluate the in vivo effect of exebacase on MRSA-infected vegetation progression when combined with daptomycin (versus daptomycin alone). Primary intravegetation outcomes were maximum size, weights at sacrifice, and MRSA counts at infection baseline versus after 4 days of daptomycin treatment (alone or in addition to exebacase administered once on treatment day 1). A single dose of exebacase in addition to daptomycin cleared significantly more intravegetation MRSA than daptomycin alone. This was associated with a statistical trend toward reduced maximum vegetation size in the exebacase plus daptomycin versus the daptomycin alone therapy groups (P = 0.07). Also, mean vegetation weights in the exebacase-treated group were significantly lower than those of the daptomycin alone group (P < 0.0001). Maximum vegetation size by TTE correlated with vegetation weight (P = 0.005). In addition, intravegetation MRSA counts in the combination group were significantly lower than those of untreated controls (P < 0.0001) and the daptomycin alone group (P < 0.0001). This study suggests that exebacase has a salutary impact on MRSA-infected vegetation progression when combined with daptomycin, especially in terms of vegetation MRSA burden, size, and weight. Moreover, TTE appears to be an efficient noninvasive tool to assess therapeutic efficacies in experimental MRSA IE.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  MRSA; echocardiography; endocarditis; phage lysin; vegetation size

Mesh:

Substances:

Year:  2020        PMID: 32340988      PMCID: PMC7317998          DOI: 10.1128/AAC.00482-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

Review 1.  Methicillin-resistant Staphylococcus aureus therapy: past, present, and future.

Authors:  Keith A Rodvold; Kevin W McConeghy
Journal:  Clin Infect Dis       Date:  2014-01       Impact factor: 9.079

Review 2.  Clinical management of Staphylococcus aureus bacteremia: a review.

Authors:  Thomas L Holland; Christopher Arnold; Vance G Fowler
Journal:  JAMA       Date:  2014-10-01       Impact factor: 56.272

3.  Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015).

Authors:  Michael A Pfaller; Rodrigo E Mendes; Jennifer M Streit; Patricia A Hogan; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

4.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-02-01       Impact factor: 9.079

5.  Role of mgrA and sarA in methicillin-resistant Staphylococcus aureus autolysis and resistance to cell wall-active antibiotics.

Authors:  María Pilar Trotonda; Yan Q Xiong; Guido Memmi; Arnold S Bayer; Ambrose L Cheung
Journal:  J Infect Dis       Date:  2009-01-15       Impact factor: 5.226

Review 6.  Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall.

Authors:  Arnold S Bayer; Tanja Schneider; Hans-Georg Sahl
Journal:  Ann N Y Acad Sci       Date:  2012-12-05       Impact factor: 5.691

Review 7.  Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment.

Authors:  Ali Hassoun; Peter K Linden; Bruce Friedman
Journal:  Crit Care       Date:  2017-08-14       Impact factor: 9.097

8.  Gain-of-Function Mutations in the Phospholipid Flippase MprF Confer Specific Daptomycin Resistance.

Authors:  Christoph M Ernst; Christoph J Slavetinsky; Sebastian Kuhn; Janna N Hauser; Mulugeta Nega; Nagendra N Mishra; Cordula Gekeler; Arnold S Bayer; Andreas Peschel
Journal:  mBio       Date:  2018-12-18       Impact factor: 7.867

9.  Bicarbonate Resensitization of Methicillin-Resistant Staphylococcus aureus to β-Lactam Antibiotics.

Authors:  Selvi C Ersoy; Wessam Abdelhady; Liang Li; Henry F Chambers; Yan Q Xiong; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

10.  Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia.

Authors:  Raymond Schuch; Han M Lee; Brent C Schneider; Karen L Sauve; Christina Law; Babar K Khan; Jimmy A Rotolo; Yuki Horiuchi; Daniel E Couto; Assaf Raz; Vincent A Fischetti; David B Huang; Robert C Nowinski; Michael Wittekind
Journal:  J Infect Dis       Date:  2013-11-28       Impact factor: 5.226

View more
  6 in total

1.  Deimmunized Lysostaphin Synergizes with Small-Molecule Chemotherapies and Resensitizes Methicillin-Resistant Staphylococcus aureus to β-Lactam Antibiotics.

Authors:  Yongliang Fang; Jack R Kirsch; Liang Li; Seth A Brooks; Spencer Heim; Cynthia Tan; Susan Eszterhas; Hao D Cheng; Hongliang Zhao; Yan Q Xiong; Karl E Griswold
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

2.  Exebacase in Addition to Daptomycin against MRSA.

Authors:  Razieh Kebriaei; Kyle C Stamper; Katherine L Lev; Taylor Morrisette; Jacinda C Abdul-Mutakabbir; Raymond Schuch; Dario Lehoux; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2021-08-16       Impact factor: 5.191

Review 3.  Exebacase: A Novel Approach to the Treatment of Staphylococcal Infections.

Authors:  Matthew W McCarthy
Journal:  Drugs R D       Date:  2022-02-17

4.  Locally delivered antistaphylococcal lysin exebacase or CF-296 is active in methicillin-resistant Staphylococcus aureus implant-associated osteomyelitis.

Authors:  Melissa Karau; Suzannah Schmidt-Malan; Jay Mandrekar; Dario Lehoux; Raymond Schuch; Cara Cassino; Robin Patel
Journal:  J Bone Jt Infect       Date:  2022-07-27

Review 5.  Native valve, prosthetic valve, and cardiac device-related infective endocarditis: A review and update on current innovative diagnostic and therapeutic strategies.

Authors:  Joop J P Kouijzer; Daniëlle J Noordermeer; Wouter J van Leeuwen; Nelianne J Verkaik; Kirby R Lattwein
Journal:  Front Cell Dev Biol       Date:  2022-10-03

6.  Efficacy of Antistaphylococcal Lysin LSVT-1701 in Combination with Daptomycin in Experimental Left-Sided Infective Endocarditis Due to Methicillin-Resistant Staphylococcus aureus.

Authors:  David B Huang; Eric Gaukel; Nancy Kerzee; Katyna Borroto-Esoda; Simon Lowry; Yan Q Xiong; Wessam Abdelhady; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.